Keppra

Product manufactured by Ucb, Inc.

Application Nr Approved Date Route Status External Links
NDA021505 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Keppra Is Indicated For The Treatment Of Partial-Onset Seizures In Patients 1 Month Of Age And Older ( 1.1 ) Keppra Is Indicated For Adjunctive Therapy For The Treatment Of: Myoclonic Seizures In Patients 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy ( 1.2 ) Primary Generalized Tonic-Clonic Seizures In Patients 6 Years Of Age And Older With Idiopathic Generalized Epilepsy ( 1.3 ) 1.1 Partial-Onset Seizures Keppra Is Indicated For The Treatment Of Partial-Onset Seizures In Patients 1 Month Of Age And Older. 1.2 Myoclonic Seizures In Patients With Juvenile Myoclonic Epilepsy Keppra Is Indicated As Adjunctive Therapy For The Treatment Of Myoclonic Seizures In Patients 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy. 1.3 Primary Generalized Tonic-Clonic Seizures Keppra Is Indicated As Adjunctive Therapy For The Treatment Of Primary Generalized Tonic-Clonic Seizures In Patients 6 Years Of Age And Older With Idiopathic Generalized Epilepsy.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Levetiracetam LEVETIRACETAM ZINC1547851

Comments